(5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane
• 化学式: C₇H₁₃N
• 分子量: 111.18
• InChiKey: BGOMFPZIMJCRDV-ZBHICJROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• DEUTERATED AMINOGLYCIDAL COMPOUNDS
  申请人：Gant Thomas G.

  公开号：US20090182057A1

  公开（公告）日：2009-07-16

  Provided herein are substituted aminoglycidyl compounds of Formula (1), processes of preparation, and pharmaceutical compositions thereof and methods of their use for treating, preventing, or ameliorating one or more symptoms of a social anxiety disorder, an anxiety disorder, hyperthyroidism, tremor, glaucoma, hypertension, coronary artery bypass graft, chronic stable angina, atrial arrhythmia, migraine, bleeding esophageal varices, hypertrophic subaortic stenosis, heart failure, post-myocardial infarction, decreased left ventricular function after recent myocardial infarction, and/or any disorder ameliorated by beta adrenergic receptor modulators.

  本文提供了一种式子为（1）的取代氨基环氧丙烷化合物，其制备方法，以及其制药组合物和用于治疗、预防或缓解社交焦虑症、焦虑症、甲状腺功能亢进、震颤、青光眼、高血压、冠状动脉搭桥手术、慢性稳定型心绞痛、心房心动过速、偏头痛、食管静脉曲张出血、肥厚性主动脉瓣下狭窄、心力衰竭、心肌梗死后、近期心肌梗死后左心室功能下降和/或任何通过β肾上腺素能受体调节剂缓解的疾病的治疗方法。
• AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2855459A1

  公开（公告）日：2015-04-08
• [EN] AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOQUINAZOLINE ET DE PYRIDOPYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013178591A1

  公开（公告）日：2013-12-05

  The invention provides novel compounds having the general formula (I): wherein A, R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.
• [EN] MULTICOMPONENT PROCESS FOR THE PREPARATION OF BICYCLIC COMPOUNDS<br/>[FR] PROCÉDÉ À MULTICOMPOSANTS POUR LA PRÉPARATION DE COMPOSÉS BICYCLIQUES
  申请人：CHEMO IBERICA SA

  公开号：WO2013178682A2

  公开（公告）日：2013-12-05

  It is described a general process, along with its possible variants, for the production of the compounds Telaprevir (I) and Boceprevir (II).